Literature DB >> 3226523

Pituitary apoplexy manifested during a bromocriptine test in a patient with a growth hormone- and prolactin-producing pituitary adenoma.

K Shirataki1, K Chihara, Y Shibata, N Tamaki, S Matsumoto, T Fujita.   

Abstract

This report describes the clinical course of pituitary apoplexy induced by a single dose of bromocriptine in a 50-year-old woman with acromegaly. The patient suddenly complained of diminished vision and headache 2 hours after the oral administration of 2.5 mg of bromocriptine. Her visual symptoms and headache persisted for several days. The basal plasma GH concentration decreased from 76.2 ng/ml to 37.2 ng/ml the day after the attack of apoplexy and to 3.0 ng/ml on the 9th day. The authors assess the changes in endocrine findings related to pituitary apoplexy and also emphasize the necessity to view with caution any symptomatic change during bromocriptine therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3226523     DOI: 10.1227/00006123-198809000-00024

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  10 in total

1.  Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Authors:  Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

2.  Pituitary apoplexy: endocrine, surgical and oncological emergency. Incidence, clinical course and treatment with reference to 799 cases of pituitary adenomas.

Authors:  W Bonicki; A Kasperlik-Załuska; W Koszewski; W Zgliczyński; J Wisławski
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

3.  Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.

Authors:  Mirta Knoepfelmacher; Miriam C Gomes; Maria E Melo; Berenice B Mendonca
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 4.  Neurological Complications of Pregnancy.

Authors:  H Steven Block
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

5.  Somatotropinoma infarction during octreotide therapy leading to bilateral cavernous sinus syndrome.

Authors:  N M Boulis; A J Noordmans; A Barkan; J Hassing; W F Chandler
Journal:  Pituitary       Date:  2000-11       Impact factor: 4.107

6.  Intratumoural cyst formation in pituitary macroadenomas.

Authors:  Z Ram; M Hadani; M Berezin; G Findler; A Sahar; I Shacked
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

7.  Remission of acromegaly following long-term therapy with cabergoline: report of two cases.

Authors:  Johan A Verhelst; Pascale J Abrams; Roger Abs
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  Cavernous sinus invasion might be a risk factor for apoplexy.

Authors:  Nese Cinar; Yasemin Tekinel; Selcuk Dagdelen; Hakan Oruckaptan; Figen Soylemezoglu; Tomris Erbas
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

9.  Pituitary apoplexy associated with endocrine stimulation test: endocrine stimulation test, treatment, and outcome.

Authors:  Takahiro Yamamoto; Shigetoshi Yano; Jun-Ichiro Kuroda; Yu Hasegawa; Takuichiro Hide; Jun-Ichi Kuratsu
Journal:  Case Rep Endocrinol       Date:  2012-08-15

10.  Bromocriptine or cabergoline induced pituitary apoplexy: Rare but life-threatening catastrophe.

Authors:  Pratibha Singh; Manish Singh; Goutham Cugati; Ajai Kumar Singh
Journal:  J Hum Reprod Sci       Date:  2011-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.